These included 42 transcription factors (e.g. FOXC1, HMGA2, RUNX2, SNAI1, SNAI2, TWIST1, and WT1), 16 protein kinases (e.g. MET, MAPK12, and AKT3), 8 homodomain proteins (including SIX4, NKX3-2, and HLX);, 27 cell differentiation markers (including PDL1, CD44, CD70, CDH2, and ITGA3), 18 oncogenes (e.g. CDH11, COL1A1, and PDGFB), 16 translocated cancer genes (CDH11, CLTCL1, COL1A1, MAF, and MAFB), one tumour suppressor gene WT1, and 38 cytokines and growth factors (including TGFB2, FGF1, VEGFC, PDGFB, EREG, TGFB1, CCL11, TGFB3, BMP1, IL1,1 and CCL13) [Pearson correlation, r>0.3, P> 0.05]. The gene discussed is RUNX2; the disease is cancer.